Scientists at Duke-NUS Medical School have identified a molecular "switch" that determines whether pancreatic cancer cells resist chemotherapy or respond to it—a finding that could help convert some ...
TME Pharma N.V. ((DE:0N6A)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Conventional pancreatic cancer treatments face a critical hurdle due to the dense tumor microenvironment (TME). This biological barrier surrounds the tumor, severely limiting the infiltration of ...
Researchers have discovered how pancreatic cancer reprograms its surroundings to spread quickly and stealthily. By using a protein called periostin, the tumor remodels nearby tissue and invades nerves ...
Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms ...
PC is a heterogeneous disease, with PDAC accounting for 90% of cases. Despite its relatively low incidence, PC is the third leading cause of cancer-related deaths in the United States, with 66,440 new ...
MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results